Creatinine- and Cystatin C-Based Incidence of Chronic Kidney Disease and Acute Kidney Disease in AKI Survivors
Table 6
Patient characteristics according to CKD classification at three months.
Variable
CKD status at 3 months (N = 199)
No CKD ()
CKD creatinine and cystatin C ()
compared to no CKD
CKD cystatin C only ()
compared to no CKD
Age
51.5 (35–62)
72.5 (66.5–81.5)
<0.001
68 (60–73)
<0.001
Gender (female)
31 (41.9%)
29 (55.8%)
0.149
30 (36.2%)
0.513
Hypertension
18 (24.2%)
34 (65.4%)
<0.001
46 (55.4%)
<0.001
Cardiovascular disease
14 (18.9%)
20 (38.5%)
0.024
33 (39.8%)
0.005
Diabetes
8 (10.8%)
18 (34.6%)
0.002
19 (22.9%)
0.057
COPD
6 (8.1%)
10 (19.3%)
0.101
15 (18.1%)
0.099
Heart failure
6 (8.1%)
9 (17.3%)
0.162
11 (13.4%)
0.316
Invasive ventilation
34 (46%)
21 (40.4%)
0.587
34 (41%)
0.627
CRRT
10 (13.5%)
14 (26.9%)
0.069
27 (32.5%)
0.008
LOS
5 (3–8)
5.5 (3–12)
0.783
8 (3–15)
0.189
Mortality at 2 years
8.1%
23.1%
0.022
13.2%
0.441
One hundred ninety-nine patients because 2 of 201 patients in whom both biomarkers were measured at follow-up 2–7 months had CKD based on creatinine but not cystatin C; their data are not presented here.
